NMTC Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Product Revenue: $2.4 million, a 72% increase year-over-year from $1.4 million in Q2 2025.
Six-Month Revenue: $5.3 million, up 13% from $4.7 million in the same period last year.
Gross Profit: $1.3 million (53.8% of product revenue) in Q2 2026, compared to $0.8 million (55.6%) in Q2 2025.
Net Loss: $2.1 million ($0.25 per share) in Q2 2026, an improvement from a $2.3 million loss ($0.44 per share) in Q2 2025.
Cash Position: $2.8 million as of March 31, 2026, down from $6.6 million as of September 30, 2025.
Working Capital: $5.7 million, decreased from $7.9 million as of September 30, 2025.

2. Strategic Updates and Business Highlights

Product Growth: Significant revenue growth attributed to the OneRF brain ablation system, with plans for domestic and international expansion.
New Appointments: David Wambeke appointed as Chief Business Officer; Ron McClurg to retire as CFO, with Chris Volker to succeed him.
Regulatory Progress: Completed Stage 2 audit for ISO 13485 certification, expected to facilitate international product distribution.
Clinical Success: 16 successful cases using the OneRF trigeminal nerve ablation system, with all patients reportedly pain-free.
Partnerships: Collaboration with the University of Minnesota for next-generation epilepsy therapies using the drug delivery platform.

3. Forward Guidance and Outlook

Revenue Guidance: Maintained product revenue growth expectation of 10.5% for fiscal 2026, excluding contributions from drug delivery and facial pain initiatives.
Commercialization Plans: Drug delivery system expected to be available in the second half of fiscal 2026 for investigational studies.
International Expansion: Plans to enter international markets with Zimmer Biomet, focusing on territories that accept FDA clearance.

4. Bad News, Challenges, or Points of Concern

Declining License Revenue: No license revenue reported in Q2 2026, down from $3 million in the first half of fiscal 2025.
Cash Decrease: Significant reduction in cash reserves, raising concerns about liquidity.
Net Loss Increase: The net loss for the first six months of fiscal 2026 increased to $3.5 million, compared to a smaller loss of $0.5 million in the prior year, primarily due to the absence of license revenue.

5. Notable Q&A Insights

Drug Delivery Strategy: Final steps include sterilization testing and validation; distributors will be used for commercialization.
Facial Pain Procedures: Surgeons are efficiently scheduling multiple procedures per day, indicating strong adoption.
International Rollout: Initial international market entry will be with Zimmer, with potential for additional distributors in non-covered territories.
Reimbursement Landscape: The trigeminal ablation procedure is being billed under an existing CPT code, but specific details were not disclosed.

Overall, NMTC reported strong revenue growth and strategic advancements but faces challenges related to cash reserves and the absence of license revenue. The outlook remains cautiously optimistic with plans for continued product development and international expansion.

NMTC — NeuroOne Medical Technologies Corporation